Pharmacokinetics in IBD: Ready for prime time?

Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, Amelie Moreau, Jean Marc Phelip, Christian Genin, Dominique Lamarque, Stephane Paul

Research output: Contribution to journalArticleOtherpeer-review

5 Citations (Scopus)


This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].

Original languageEnglish
Pages (from-to)1049-1055
Number of pages7
JournalCurrent Drug Targets
Issue number11
Publication statusPublished - 1 Jan 2014


  • Anti TNF treatment
  • Antibodies to anti TNF
  • Crohn’s disease
  • Optimisation
  • Trough levels of anti TNF
  • Ulcerative colitis

Cite this